Evaluation of clinical value of plasma miRNA-20a and miRNA-210 in diagnosis of lung cancer
XIA Xian-bin1, LI Jian1, WANG Yi2
(1. Department of Respiratory Medicine, 2. Center of Medical Experiment, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China)
Abstract:Objective: To evaluate the diagnostic values of plasma miRNA20a and miRNA210 expression for lung cancer. Methods: The expression levels of plasma miRNA20a and miRNA210 were determined by fluorescence quantitative PCR in 58 lung cancer patients and 46 benign lung disease patients(cancerfree controls). The correlations between the two miRNAs levels in plasma and clinicopathological characteristics of patients with lung cancer were analyzed. The diagnostic performance of each miRNA to distinguish lung cancer from benign lung disease was evaluated using the receiver operating characteristic(ROC) curve analysis. According to the optimal cutoff point chosen by ROC curve analysis, sensitivity, specificity, positive value(PPV), negative predictive value (NPV) and accuracy were calculated. The diagnostic value of the two miRNAs for lung cancer was compared with tumor markers carcinoembryonic antigen(CEA) and Cyfra211. Results: The levels of plasma miRNA20a and miRNA210 in lung cancer patients were significantly elevated than those in benign lung disease patients (P<0.01). No significant correlation was found between plasma miRNA20a levels and clinicopathological characteristics of lung cancer patients, whereas the expression levels of plasma miRNA210 was significantly correlated with tumor histological types, differential degree and clinical stages(P=0.008, P=0.041 and P=0.016). The area under ROC curve of the two miRNAs were 0.883(95%CI, 0.821-0.946)and 0.824(95%CI, 0.745-0.904), which were higher than those of CEA (0.656, 95%CI, 0.551-0.761) and Cyfra211(0.754, 95%CI, 0.658-0.847), respectively. The sensitivity(77.6% and 75.9%) and accuracy(81.7% and 77.9%) of plasma miRNA20a and miRNA210 for diagnosing lung cancer were higher than those of CEA(44.8% and 62.5%) and Cyfra211(56.9% and 72.1%). And the sensitivity was increased with miRNA20a in combination with miRNA210. Moreover, the combination of plasma miRNA20a and miRNA210 with CEA or Cyfra211 further raised the sensitivity in diagnosis of lung cancer, despite slightly decreased specificity. Conclusion: Plasma miRNA20a and miRNA210 may be used as promising biomarkers in the diagnosis of lung cancer.
夏贤斌1, 李坚1, 汪毅2. 血浆miRNA-20a和miRNA-210对肺癌的诊断价值评价[J]. 江苏大学学报:医学版, 2017, 27(01): 47-52.
XIA Xian-bin1, LI Jian1, WANG Yi2. Evaluation of clinical value of plasma miRNA-20a and miRNA-210 in diagnosis of lung cancer. Journal of Jiangsu University(Medicine Edition), 2017, 27(01): 47-52.
[1\]Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction\[J\]. Nat Rev Mol Cell Biol, 2010, 11(4):252-263.\[2\]Qi J, Mu D. MicroRNAs and lung cancers: from pathogenesis to clinical implications \[J\]. Front Med, 2012, 6(2):134-155.\[3\]Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics\[J\]. Biomark Res, 2014, 2:19.\[4\]Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating microRNA expression profiles in early stage nonsmall cell lung cancer\[J\].Int J Cancer,2012, 130(6):1378-1386.\[5\]Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer\[J\]. Cancer Res, 2009, 69(14):5776-5783.\[6\]Tan X, Qin W, Zhang L, et al. A 5microRNA signature for lung squamous cell carcinoma diagnosis and hsamiR31 for prognosis\[J\].Clin Cancer Res,2011, 17(21):6802-6811.\[7\]Dacic S, Kelly L,Shuai Y,et al. MiRNA expression profiling of lung adenocarcinomas: correlation with mutational status \[J\]. Mod Pathol, 2010, 23(12):1577-1582.\[8\]Shi SB, Wang M, Tian J, et al. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations\[J\].Transl Res,2016, 170:1-7.\[9\]Zhu W, Liu X, He J, et al. Overexpression of members of the microRNA183 family is a risk factor for lung cancer: a case control study \[J\]. BMC Cancer, 2011, 11:393.\[10\]朱立欢, 李坚,朱宇敏, 等. 肺癌患者血浆miR1973p和miR3613p表达的诊断评价\[J\]. 江苏大学学报(医学版), 2015, 25(2): 149-154.\[11\]费玲, 李坚, 朱立欢, 等. 血浆miRNA155和miRNA625用于非小细胞肺癌诊断的临床评价\[J\]. 江苏大学学报(医学版), 2015, 25(3): 236-245.\[12\]Lan D, Zhang X, He R, et al. MiR133a is downregulated in nonsmall cell lung cancer: a study of clinical significance\[J\]. Eur J Med Res, 2015, 20:50.\[13\]王亚南, 史进芳, 吴元健, 等. 肺癌与癌旁组织中miR20a的定量检测及其意义\[J\]. 临床检验杂志, 2011, 29(2): 135-137.\[14\]Osuql J,Klmura Y,Owada Y,et al.Prognostic impact of hypoxiainducible miRNA210 in patients with lung adenocarcinoma\[J\]. J Oncol,2015, 2015:316745.\[15\]Sanfiorenzo C, Ilie Ml, Belaid A, et al. Two panels of plasma microRNAs as noninvasive biomarkers for prediction of recurrence in resectable NSCLC\[J\]. PLoS One, 2013, 8(1):e54596.\[16\]Geng Q, Fan T, Zhang B, et al. Five microRNAs in plasma as novel biomarkers for screening of earlystage nonsmall cell lung cancer\[J\]. Respir Res, 2014, 15:49.\[17\]Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers\[J\]. BMC Cancer, 2011, 11:374.\[18\]Patnaik SK, Yendamuri S, Kannisto E, et al. MicroRNA expression profiles of whole blood in lung adenocarcinoma\[J\]. PLoS One, 2012, 7(9):e46045. doi: 10.1371/journal.pone.0046045.\[19\]Tsuchiya S, Fujiwara T,Sato F,et al.MicroRNA210 regulates cancer cell proliferation through targeting fibroblast growth factor receptorlike 1(FGFRL1)\[J\].J Biol Chem,2011,286(1): 420-428.\[20\]Ono S,Oyama T, Lam S, et al. A direct plasma assay of circulating microRNA210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients\[J\]. Oncotarget, 2015, 6(9):7053-7064.\[21\]Rosjo H, Dahl MB, Bye A, et al. Prognostic value of circulating microRNA210 levels in patients with moderate to severe aortic stenosis\[J\]. PLoS One,2014, 9(3):e91812.\[22\]Yamasaki K, Nakasa T,Miyaki S, et al. Angiogenic microRNA210 is present in cells surrounding osteonecrosis \[J\]. J Orthop Res, 2012, 30(8):1263-1270.\[23\]Greither T, Wurl P, Grochola L, et al. Expression of microRNA 210 associates with poor survival and age of tumor onset of softtissue sarcoma patients\[J\]. Int J Cancer, 2012, 130(5):1230-1235.\[24\]Olive V, Jiang I, He L. Mir1792, a cluster of miRNAs in the midst of the cancer network\[J\]. Lnt J Biochem Cell Biol, 2010, 42(8):1348-1354.\[25\]Faraonio R, Salerno P, Passaro F, et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts\[J\]. Cell Death Differ,2012, 19(4):713-721.